SG11201505924TA - Factor viii polypeptide formulations - Google Patents

Factor viii polypeptide formulations

Info

Publication number
SG11201505924TA
SG11201505924TA SG11201505924TA SG11201505924TA SG11201505924TA SG 11201505924T A SG11201505924T A SG 11201505924TA SG 11201505924T A SG11201505924T A SG 11201505924TA SG 11201505924T A SG11201505924T A SG 11201505924TA SG 11201505924T A SG11201505924T A SG 11201505924TA
Authority
SG
Singapore
Prior art keywords
factor viii
viii polypeptide
polypeptide formulations
formulations
factor
Prior art date
Application number
SG11201505924TA
Other languages
English (en)
Inventor
Kevin Maloney
Ahmad Abdul-Fattah
Daniel Gage
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201505924T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of SG11201505924TA publication Critical patent/SG11201505924TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201505924TA 2013-03-15 2014-03-14 Factor viii polypeptide formulations SG11201505924TA (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30
PCT/US2014/029354 WO2014144795A1 (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Publications (1)

Publication Number Publication Date
SG11201505924TA true SG11201505924TA (en) 2015-09-29

Family

ID=50771579

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201805207QA SG10201805207QA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations
SG11201505924TA SG11201505924TA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201805207QA SG10201805207QA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Country Status (21)

Country Link
US (3) US9623088B2 (es)
EP (3) EP3666283B1 (es)
JP (5) JP6330026B2 (es)
AU (3) AU2014228506A1 (es)
CA (1) CA2899737A1 (es)
CL (1) CL2015002720A1 (es)
DK (1) DK2968477T3 (es)
EA (2) EA030357B1 (es)
ES (2) ES2926798T3 (es)
HK (1) HK1220617A1 (es)
HU (1) HUE047933T2 (es)
LT (1) LT2968477T (es)
PH (2) PH12015501801B1 (es)
PL (2) PL2968477T3 (es)
PT (2) PT2968477T (es)
RS (1) RS60003B1 (es)
SG (2) SG10201805207QA (es)
SI (1) SI2968477T1 (es)
TW (2) TWI629993B (es)
UY (1) UY35462A (es)
WO (1) WO2014144795A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5903048B2 (ja) * 2009-12-06 2016-04-13 バイオジェン ヘモフィリア インコーポレイテッド 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法
TWI629993B (zh) * 2013-03-15 2018-07-21 美商生物化學醫療公司 因子ｖｉｉｉ多肽調配物
SG10201707600XA (en) 2013-03-15 2017-11-29 Biogen Ma Inc Factor ix polypeptide formulations
CN106317226B (zh) 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
CN106279437B (zh) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
AU2017368328A1 (en) 2016-12-02 2019-07-18 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
US20190381149A1 (en) 2016-12-02 2019-12-19 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
JP7039308B2 (ja) * 2017-02-08 2022-03-22 三洋化成工業株式会社 細胞培養用担体
AU2018313921A1 (en) 2017-08-09 2020-03-12 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof
JP7370974B2 (ja) 2017-11-07 2023-10-30 ラニ セラピューティクス， エルエルシー 嚥下可能薬物送達デバイスを使用する腸管組織への送達のための凝固因子調製物
MX2020012397A (es) 2018-05-18 2021-04-12 Bioverativ Therapeutics Inc Metodos de tratamiento de la hemofilia a.
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
CN113301911A (zh) * 2018-10-23 2021-08-24 费城儿童医院 用于调节因子viii功能的组合物和方法
JP7501875B2 (ja) * 2019-02-28 2024-06-18 公立大学法人横浜市立大学 血液凝固および／または補体異常疾患の治療用組成物
JP2022531095A (ja) 2019-04-17 2022-07-06 コディアック バイオサイエンシーズ， インコーポレイテッド エキソソーム及びａａｖの組成物
US20220233650A1 (en) 2019-06-19 2022-07-28 Bioverativ Therapeutics Inc. Recombinant factor viii-fc for treating hemophilia and low bone mineral density
KR20230159284A (ko) * 2022-05-10 2023-11-21 주식회사 녹십자 혈장 단백질에 대한 신규한 액상 제형물
TW202400224A (zh) * 2022-05-10 2024-01-01 南韓商綠十字股份有限公司 用於冷凍乾燥血漿蛋白之新穎液體調配物

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
ES8801674A1 (es) 1985-04-12 1988-02-16 Genetics Inst Un procedimiento para la preparacion de una proteina que presenta actividad procoagulante.
KR910006424B1 (ko) 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
ATE87663T1 (de) 1986-01-03 1993-04-15 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ- proteinen.
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IE69026B1 (en) 1987-06-12 1996-08-07 Immuno Ag Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
DE3720246A1 (de) 1987-06-19 1988-12-29 Behringwerke Ag Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
FR2619314B1 (fr) 1987-08-11 1990-06-15 Transgene Sa Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
DE69029799T2 (de) 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. Modifizierte formen von fortpflanzungshormonen
SE465222C5 (sv) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
AU1674292A (en) 1991-03-15 1992-10-21 Synergen, Inc. Pegylation of polypeptides
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
CZ290342B6 (cs) 1992-10-02 2002-07-17 Genetics Institute Inc. Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (sv) 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (sv) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
PT2193809E (pt) * 1999-02-22 2015-08-24 Baxter Int Formulações de fator viii livres de albumina
MXPA02007733A (es) 2000-02-11 2004-09-10 Merck Patent Gmbh Mejoramiento de la vida media circulante de proteinas de fusion basadas en anticuerpos.
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
EP2298347B1 (en) 2003-05-06 2015-09-30 Biogen Hemophilia Inc. Clotting factor chimeric proteins for treatment of a hemostatic disorder
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
WO2005058283A2 (en) * 2003-12-19 2005-06-30 Novo Nordisk Health Care Ag Stabilised compositions of factor vii polypeptides
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
DK1824988T3 (en) 2004-11-12 2017-08-07 Bayer Healthcare Llc LOCATION-SPECIFIC MODIFICATION OF FVIII
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
EP1988922A4 (en) * 2006-02-03 2010-06-02 Medimmune Llc PROTEIN FORMULATIONS
KR101542752B1 (ko) * 2006-12-22 2015-08-10 체에스엘 베링 게엠베하 연장된 생체내 반감기를 갖는 변형된 응고 인자
ATE502114T1 (de) 2007-06-21 2011-04-15 Univ Muenchen Tech Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
JP5647899B2 (ja) 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
ES2427627T3 (es) * 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
JP5903048B2 (ja) * 2009-12-06 2016-04-13 バイオジェン ヘモフィリア インコーポレイテッド 第ＶＩＩＩ−Ｆｃ因子キメラおよびハイブリッドポリペプチドならびにその使用法
PT3513804T (pt) 2011-07-08 2022-06-02 Bioverativ Therapeutics Inc Polipéptidos fator viii híbridos e quiméricos, e métodos de utilização dos mesmos
AU2012318292B2 (en) 2011-10-18 2015-08-20 Csl Limited Method for improving the stability of purified Factor VIII after reconstitution
EP2882457A1 (en) 2012-08-13 2015-06-17 Novo Nordisk A/S Liquid factor viii formulations
EP3943102A1 (en) * 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
TWI629993B (zh) * 2013-03-15 2018-07-21 美商生物化學醫療公司 因子ｖｉｉｉ多肽調配物

Also Published As

Publication number Publication date
EP2968477A1 (en) 2016-01-20
TW201501722A (zh) 2015-01-16
PH12015501801A1 (en) 2015-11-09
ES2776195T3 (es) 2020-07-29
JP6934994B2 (ja) 2021-09-15
TWI629993B (zh) 2018-07-21
HK1220617A1 (zh) 2017-05-12
EP3666283A1 (en) 2020-06-17
AU2014228506A1 (en) 2015-08-13
AU2021277601A1 (en) 2021-12-23
PL3666283T3 (pl) 2022-10-03
SG10201805207QA (en) 2018-07-30
WO2014144795A1 (en) 2014-09-18
US20140308280A1 (en) 2014-10-16
PT2968477T (pt) 2020-03-11
EA201591439A1 (ru) 2016-03-31
EP2968477B1 (en) 2019-12-04
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
PH12015501801B1 (en) 2015-11-09
PT3666283T (pt) 2022-09-13
PH12019502452A1 (en) 2021-02-08
CL2015002720A1 (es) 2016-11-04
UY35462A (es) 2014-10-31
RS60003B1 (sr) 2020-04-30
SI2968477T1 (sl) 2020-04-30
US20170281734A1 (en) 2017-10-05
PL2968477T3 (pl) 2020-06-15
US20210069300A1 (en) 2021-03-11
EP3666283B1 (en) 2022-06-08
JP6330026B2 (ja) 2018-05-23
EA030357B1 (ru) 2018-07-31
JP2021181491A (ja) 2021-11-25
US10786554B2 (en) 2020-09-29
TWI690325B (zh) 2020-04-11
EP4122487A1 (en) 2023-01-25
EA201890671A1 (ru) 2019-01-31
JP2018123161A (ja) 2018-08-09
US9623088B2 (en) 2017-04-18
CA2899737A1 (en) 2014-09-18
ES2926798T3 (es) 2022-10-28
JP7240457B2 (ja) 2023-03-15
JP2023060146A (ja) 2023-04-27
LT2968477T (lt) 2020-03-10
HUE047933T2 (hu) 2020-05-28
TW201842930A (zh) 2018-12-16
JP2016516722A (ja) 2016-06-09
DK2968477T3 (da) 2020-03-09
JP2020186268A (ja) 2020-11-19

Similar Documents

Publication Publication Date Title
HK1220617A1 (zh) 因子 多肽調配物
EP3065716C0 (en) FORMULATIONS
HK1220697A1 (zh) 肽組合物
HK1220619A1 (zh) 因子 多肽調配物
HRP20180452T1 (hr) Peptidi
HK1213273A1 (zh) 重組因子 製劑
HK1220366A1 (zh) 蛋白製劑
HK1211596A1 (en) Peptide
HK1211595A1 (en) Peptide
GB201315130D0 (en) Peptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides